Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash from Restructuring (2016 - 2017)

Altimmune (ALT) has disclosed Cash from Restructuring for 3 consecutive years, with -$66633.0 as the latest value for Q1 2017.

  • On a quarterly basis, Cash from Restructuring rose 66.13% to -$66633.0 in Q1 2017 year-over-year; TTM through Mar 2017 was -$267300.0, a 83.84% increase, with the full-year FY2016 number at -$397383.0, down 182.49% from a year prior.
  • Cash from Restructuring was -$66633.0 for Q1 2017 at Altimmune, roughly flat from -$66633.0 in the prior quarter.
  • In the past five years, Cash from Restructuring ranged from a high of $1.9 million in Q1 2015 to a low of -$1.1 million in Q2 2015.
  • A 3-year average of $1971.7 and a median of -$66727.0 in 2016 define the central range for Cash from Restructuring.
  • Biggest YoY gain for Cash from Restructuring was 94.19% in 2016; the steepest drop was 762.99% in 2016.
  • Altimmune's Cash from Restructuring stood at -$319008.0 in 2015, then soared by 79.11% to -$66633.0 in 2016, then changed by 0.0% to -$66633.0 in 2017.
  • Per Business Quant, the three most recent readings for ALT's Cash from Restructuring are -$66633.0 (Q1 2017), -$66633.0 (Q4 2016), and -$67307.0 (Q3 2016).